BioCardia (NASDAQ:BCDA) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of BioCardia (NASDAQ:BCDA – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $4.00 target price on the stock. HC Wainwright also issued estimates for BioCardia’s Q4 2023 earnings at ($0.10) EPS, FY2023 earnings at ($0.46) EPS, FY2024 earnings at […]

Leave a Reply

Your email address will not be published.

Previous post JMP Securities Trims Viridian Therapeutics (NASDAQ:VRDN) Target Price to $38.00
Next post BMO Capital Markets Cuts BSR Real Estate Investment Trust (TSE:HOM.UN) Price Target to C$13.50